CVE detail

CVE-2020-10627 — CVE-2020-10627

Published 2021-12-01 · Modified 2026-06-17 · Vendor insulet · Product omnipod_insulin_management_system_firmware · Source nvd
HIGH
severity
CVSS-derived band
7.3
CVSS v3
0–10 scale
0.0048
EPSS probability
exploitation probability, 30d
39.0%
EPSS percentile
percentile vs all CVEs
NOT LISTED
CISA KEV
known exploited catalog

Description

Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.

Remediation

No vendor-published fix data in our corpus for this CVE. Check the references below or the vendor's PSIRT / security advisories page.

References

cvedb.io · NVD · CISA KEV · FIRST EPSS · vendor advisories (CVE Program List v5). Informational only, no warranty — verify every remediation against the vendor advisory before acting on it. This product uses data from the NVD API but is not endorsed or certified by the NVD, CISA, FIRST.org or any vendor named. CVE® is a registered trademark of The MITRE Corporation.